Iloprost FDA Link

An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.

Also Known As:

Ventavis; ZK-36374; ZK 36374; ZK36374; Ciloprost; Pentanoic acid, 5- (hexahydro- 5- hydroxy- 4- (3- hydroxy- 4- methyl- 1- octen- 6- ynyl)- 2(1H)- pentalenylidene)-

Pharmalogical Action Categories:

Platelet Aggregation Inhibitors
Vasodilator Agents

Lipids: 118169
- Fatty Acids: 28212
  - Unsaturated Fatty Acids: 8458
    - Eicosanoids: 3282
      - Prostaglandins: 17184
        Synthetic Prostaglandins: 835
        Iloprost: 1186
Biological Factors: 2560
- Inflammation Mediators: 1126
  - Synthetic Prostaglandins: 835
    - Iloprost: 1186
  - Autacoids: 278
    - Eicosanoids: 3282
      - Prostaglandins: 17184
        Synthetic Prostaglandins: 835
        Iloprost: 1186

Iloprost Therapy on Pulmonary Hypertension Study Group Selected Research

Iloprost Therapy on Pulmonary Hypertension Study Group Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure